
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6123800/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient. Nefrologia, 2022, 42, 130-134.	0.2	1
2	CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood, 2022, 139, 792-796.	0.6	34
3	Hidden in the Eyes—Recurrence of Systemic Hemopathies Reportedly "In Remissionâ€: Six Cases and Review of Literature. Medicina (Lithuania), 2022, 58, 456.	0.8	2
4	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network. Bone Marrow Transplantation, 2022, 57, 966-974.	1.3	12
5	Immunochemotherapy versus rituximab in antiâ€myelinâ€associated glycoprotein neuropathy: A report of 64 patients. British Journal of Haematology, 2022, , .	1.2	6
6	Primary CNS lymphoma of the corpus callosum: presentation and neurocognitive outcomes. Journal of Neuro-Oncology, 2022, , 1.	1.4	2
7	Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient. Nefrologia, 2022, 42, 130-134.	0.2	0
8	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological Oncology, 2022, 40, 976-986.	0.8	2
9	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. Journal of Clinical Oncology, 2022, 40, 3692-3698.	0.8	31
10	Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. Journal of Neurology, 2021, 268, 2141-2150.	1.8	4
11	Chimeric antigen receptor <scp>T</scp> â€cells safety: A pharmacovigilance and metaâ€analysis study. American Journal of Hematology, 2021, 96, 1101-1111.	2.0	14
12	Successful treatment of an EBVâ€positive HIVâ€associated polymorphic Bâ€cell lymphoproliferative disorder by rituximab monotherapy. EJHaem, 2021, 2, 562-564.	0.4	1
13	Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. American Journal of Transplantation, 2021, 21, 2846-2863.	2.6	7
14	Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. Current Opinion in Oncology, 2021, 33, 420-431.	1.1	8
15	Managing immunosuppressive therapy in potentially cured postâ€kidney transplant cancer (excluding) Tj ETQq1 I decisionâ€making. Transplant International, 2021, 34, 1789-1800.	1 0.78431 0.8	4 rgBT /Ove 8
16	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8
17	Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations. Frontiers in Cell and Developmental Biology, 2021, 9, 661272.	1.8	6
18	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189

#	Article	IF	CITATIONS
19	In situ offâ€line extracorporeal photopheresis conducted in a realâ€life situation at a Hemobiotherapy Department in France: A comparison of costs vs onâ€line procedure. Journal of Clinical Apheresis, 2021, ,	0.7	1
20	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. Blood, 2021, 138, 885-885.	0.6	5
21	Radical Improvement in Prognosis of CNS Ptlds Using Methotrexate Dose Alorithm Regardless of Renal Function. Blood, 2021, 138, 2521-2521.	0.6	1
22	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. Blood, 2021, 138, 452-452.	0.6	1
23	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1
24	Management and outcome of primary CNS lymphoma in the modern era. Neurology, 2020, 94, e1027-e1039.	1.5	125
25	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood, 2020, 135, 1811-1815.	0.6	17
26	Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study. Journal of Neuro-Oncology, 2020, 148, 343-352.	1.4	15
27	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematology,the, 2020, 7, e511-e522.	2.2	201
28	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	3.3	54
29	18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma. Clinical Nuclear Medicine, 2020, 45, e206-e207.	0.7	2
30	Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Advances, 2020, 4, 1357-1366.	2.5	29
31	Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
32	Optimization of CSF biological investigations for CNS lymphoma diagnosis. American Journal of Hematology, 2019, 94, 1123-1131.	2.0	9
33	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S248-S249.	0.2	1
34	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drugâ€resistant chronic lymphocytic leukemia. Cancer Medicine, 2019, 8, 3131-3141.	1.3	10
35	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. Neuro-Oncology, 2019, 21, 1039-1048.	0.6	13
36	Automated differential white blood cell count and cytological analysis can detect nearâ€ŧetraploid cells in chronic lymphoproliferative disorders. International Journal of Laboratory Hematology, 2019, 41, e104-e108.	0.7	0

#	Article	IF	CITATIONS
37	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. Journal of Clinical Oncology, 2019, 37, 823-833.	0.8	184
38	MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e253-e254.	0.2	0
39	A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e41.	0.2	1
40	Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study. Leukemia and Lymphoma, 2019, 60, 1563-1567.	0.6	0
41	The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. Hematology, 2019, 24, 173-182.	0.7	16
42	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	6.3	517
43	A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancyâ€associated secondary immunodeficiency. European Journal of Haematology, 2018, 101, 48-56.	1.1	18
44	Endogenous Metabolitesâ€Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between <i>SLCO1B1</i> SNPs and Methotrexate Toxicity. Clinical Pharmacology and Therapeutics, 2018, 104, 687-698.	2.3	32
45	Impact of plerixafor (mozobil) on hospital efficiency: A single center experience. Journal of Clinical Apheresis, 2018, 33, 5-13.	0.7	7
46	Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications. International Journal of Peptide Research and Therapeutics, 2018, 24, 479-488.	0.9	12
47	A clinical trial combining megakaryocytes and haematopoietic stem cells to promote engraftment after autologous transplantation. British Journal of Haematology, 2018, 183, 139-142.	1.2	Ο
48	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Seminars in Hematology, 2018, 55, 179-181.	1.8	7
49	Post-Heart Transplantation Lymphoproliferations. , 2018, , .		0
50	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S249-S250.	0.2	6
51	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Transplantation, 2018, 102, 1914-1923.	0.5	11
52	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. Blood, 2018, 132, 1677-1677.	0.6	2
53	Glomeruloid haemangioma: a possible consequence of elevated VEGF in POEMS and Erdheim-Chester disease. European Journal of Dermatology, 2018, 28, 784-789.	0.3	1
54	Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance. Pharmacological Research, 2017, 118, 121-132.	3.1	22

#	Article	IF	CITATIONS
55	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	0.8	168
56	Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. Leukemia and Lymphoma, 2017, 58, 1366-1375.	0.6	6
57	Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. Journal of Neuro-Oncology, 2017, 133, 315-320.	1.4	47
58	Human Herpesvirus 6 (HHV-6) necrotizing encephalitis, a rare condition in immunocompromised patients: The importance of brain biopsy associated with HHV-6 testing. Journal of the Neurological Sciences, 2017, 377, 112-115.	0.3	5
59	A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. Therapeutic Drug Monitoring, 2017, 39, 145-156.	1.0	12
60	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer, 2017, 25, 3295-3304.	1.0	64
61	Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients. British Journal of Haematology, 2017, 176, 37-49.	1.2	32
62	lbrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. Neurology, 2017, 88, 101-102.	1.5	65
63	Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma. Leukemia and Lymphoma, 2017, 58, 729-731.	0.6	1
64	Immunotherapy in Waldenstrom's Macroglobulinemia. , 2017, , 315-326.		0
65	Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes. , 2017, , .		2
66	Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology, 2016, 19, now238.	0.6	30
67	Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. Ophthalmology, 2016, 123, 2047-2050.	2.5	17
68	Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. Journal of Clinical Oncology, 2016, 34, 2125-2132.	0.8	91
69	Post-transplant lymphoproliferative disorders. Nature Reviews Disease Primers, 2016, 2, 15088.	18.1	161
70	Efficacy and longâ€ŧerm toxicity of the rituximabâ€fludarabineâ€cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. American Journal of Hematology, 2016, 91, 782-786.	2.0	27
71	The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. European Journal of Cancer, 2016, 61, 69-76.	1.3	66
72	Neither the patient nor the physician could see anything: Atypical Bing–Neel syndrome. American Journal of Hematology, 2016, 91, 858-859.	2.0	2

#	Article	IF	CITATIONS
73	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncology, 2016, 18, 1297-1303.	0.6	135
74	Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013. Blood, 2016, 128, 4230-4230.	0.6	1
75	Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group. Blood, 2016, 128, 4612-4612.	0.6	4
76	Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS). Blood, 2016, 128, 782-782.	0.6	21
77	Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network. Blood, 2016, 128, 784-784.	0.6	34
78	Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. Blood, 2016, 128, 785-785.	0.6	39
79	The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. Blood, 2016, 128, 926-926.	0.6	2
80	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e251-e259.	2.2	164
81	Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica, 2015, 100, 1199-1206.	1.7	30
82	Lenalidomide is safe and active in <scp>W</scp> aldenström macroglobulinemia. American Journal of Hematology, 2015, 90, 1055-1059.	2.0	23
83	Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. Neurology, 2015, 84, 325-326.	1.5	84
84	Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases. Blood, 2015, 126, 1524-1524.	0.6	6
85	Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients. Blood, 2015, 126, 2948-2948.	0.6	1
86	To Dose or Not to Dose: Are IL-10 and IL-6 Accurate Biomarkers to Detect Leptomeningeal Involvement in Small B-Cell Lymphoproliferation?. Blood, 2015, 126, 3878-3878.	0.6	1
87	The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 492-492.	0.6	1
88	Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. Blood, 2015, 126, 816-816.	0.6	5
89	Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia. Protein and Peptide Letters, 2015, 22, 539-546.	0.4	12
90	Current and future therapeutic approach for Waldenström's macroglobulinemia. Immunotherapy, 2014, 6, 333-348.	1.0	1

#	Article	IF	CITATIONS
91	Improved relapseâ€free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantationâ€Intergroup study. American Journal of Hematology, 2014, 89, 174-180.	2.0	10
92	Sex chromosome loss may represent a diseaseâ€associated clonal population in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 240-247.	1.5	22
93	T-cell Therapy Using a Bank of EBV-specific Cytotoxic T Cells. Journal of Immunotherapy, 2014, 37, 170-179.	1.2	42
94	Urinary coproporphyrin <scp>I</scp> /(<scp>I</scp> + <scp>III</scp>) ratio as a surrogate for <scp>MRP2</scp> or other transporter activities involved in methotrexate clearance. British Journal of Clinical Pharmacology, 2014, 78, 329-342.	1.1	16
95	CNS involvement at diagnosis in mantle cell lymphoma with atypical MRI features. Journal of Neurology, 2014, 261, 1018-1020.	1.8	5
96	Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial. Blood, 2014, 124, 3341-3341.	0.6	4
97	Use of Human Immunoglobulins in Secondary Immunodeficiencies Associated with Hematological Malignancy in Real-Life Practice: Which Patients, Which Treatment?. Blood, 2014, 124, 4972-4972.	0.6	1
98	Lenalidomide in the treatment of relapsed primary central nervous system lymphoma (PCNSL) Journal of Clinical Oncology, 2014, 32, 2079-2079.	0.8	1
99	High Efficiency and Tolerance of Temozolomide in Relapse/Refractory Primary Intra-Ocular Lymphoma (R/R PIOL). a Retrospective Multicentric Study from the LOC Network. Blood, 2014, 124, 3080-3080.	0.6	Ο
100	IL10 and IL10:IL6 Ratio in CSF Is Useful at Diagnosis but Also in the Assessment of Therapeutic Response in Patients with Primary Central Nervous System Lymphoma (PCNSL). Blood, 2014, 124, 1619-1619.	0.6	2
101	Risk and Response Adapted Conventional Treatment Strategy in 146 Patients with AL Amyloidosis. Blood, 2014, 124, 2131-2131.	0.6	9
102	Fludarabine in Waldenstrom's macroglobulinemia. Expert Review of Hematology, 2013, 6, 229-237.	1.0	2
103	Granulomatous angiitis of the CNS revealing a Hodgkin lymphoma. Neurology, 2013, 80, 323-324.	1.5	19
104	Primary Therapy of Waldenström Macroglobulinemia With Nucleoside Analogue–Based Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 227-230.	0.2	3
105	Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated WaldenstrA¶m Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. Journal of Clinical Oncology, 2013, 31, 301-307.	0.8	146
106	Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score. Journal of Clinical Oncology, 2013, 31, 1302-1309.	0.8	122
107	Efficacy of lenalidomide in <scp>POEMS</scp> syndrome: A retrospective study of 20 patients. American Journal of Hematology, 2013, 88, 207-212.	2.0	59
108	Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica, 2013, 98, e155-e157.	1.7	30

#	Article	IF	CITATIONS
109	Early and Late Posttransplant Lymphoproliferative Disorder After Lung Transplantation—34 Cases From the European PTLD Network. Transplantation, 2013, 96, e18-e19.	0.5	8
110	The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients. Blood, 2013, 122, 2193-2193.	0.6	2
111	Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study Journal of Clinical Oncology, 2013, 31, 2032-2032.	0.8	9
112	Recurrent Mutations of <i>MYD88</i> and <i>TBL1XR1</i> in Primary Central Nervous System Lymphomas. Clinical Cancer Research, 2012, 18, 5203-5211.	3.2	210
113	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica, 2012, 97, 1751-1756.	1.7	95
114	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncology, The, 2012, 13, 196-206.	5.1	349
115	Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal of Neuro-Oncology, 2012, 106, 143-146.	1.4	51
116	High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory Primary Central-Nervous System and Intra-Ocular Non Hodgkin Lymphoma, After First Line Treatment Containing High Doses of Methotrexate and Cytarabine. A Monocentric Retrospective Study From 2010 to 2012 On 17 Cases. Blood, 2012, 120, 3664-3664.	0.6	2
117	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW. Blood, 2012, 120, 716-716.	0.6	7
118	Familial Chronic lymphoid leukemia (CLL): state of the art. Hematologie, 2012, 18, 182-188.	0.0	1
119	Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood, 2011, 117, 1516-1521.	0.6	60
120	Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?. Journal of Neuro-Oncology, 2011, 104, 323-330.	1.4	54
121	Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. Journal of Neuro-Oncology, 2011, 105, 409-414.	1.4	18
122	Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leukemia and Lymphoma, 2011, 52, 238-246.	0.6	22
123	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. Blood, 2011, 118, 2854-2854.	0.6	2
124	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. Blood, 2011, 118, 879-879.	0.6	3
125	Bone involvement in two cases of thoracic primary cutaneous diffuse large B-cell lymphoma, leg type. European Journal of Dermatology, 2011, 21, 744-749.	0.3	3
126	Pulmonary Infiltration in Anaplastic T-Cell Lymphoma. , 2011, , 787-791.		0

Pulmonary Infiltration in Anaplastic T-Cell Lymphoma. , 2011, , 787-791.

#	Article	IF	CITATIONS
127	Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial. Blood, 2011, 118, 878-878.	0.6	0
128	Anti-MAG Neuropathy: a Single Center Retrospective Study In 61 Patients. Blood, 2010, 116, 3951-3951.	0.6	0
129	Adapted Management of EBV Reactivation After Solid Organ Transplantation: An Effective Prevention of Post Transplantation Lymphoproliferative Disorders (PTLD). Results of the Largest Prospective Study on 251 Patients. Blood, 2010, 116, 592-592.	0.6	0
130	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial Blood, 2009, 114, 100-100.	0.6	6
131	Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group Blood, 2009, 114, 3408-3408.	0.6	0
132	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leukemia and Lymphoma, 2008, 49, 2012-2014.	0.6	23
133	Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal of Clinical Oncology, 2008, 26, 2512-2518.	0.8	301
134	Results of the Largest Study on Post-Transplant-Lymphoproliferations (PTLDs) of the Central Nervous System (CNS) in the Rituximab Era: A Surprising Overrepresentation of Kidney Transplantations, Key Importance of Methotrexate (Mtx), Cytarabine (AraC) and Radiotherapy (RX) for Long Term Survival and Low Impact of Rituximab (R). Blood, 2008, 112, 3614-3614.	0.6	5
135	Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation, 2007, 84, 1708-1712.	0.5	34
136	CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation. Haematologica, 2007, 92, 273-274.	1.7	143
137	Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. Joint Bone Spine, 2007, 74, 446-452.	0.8	18
138	Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Annals of Hematology, 2007, 86, 599-607.	0.8	122
139	Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenstrol̀^m's Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French) Tj ETQq1 1 0.78	430 .4 rgBT	'/Overlock 1
140	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy? Blood, 2007, 110, 390-390.	0.6	6
141	FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma Blood, 2007, 110, 413-413.	0.6	5
142	A Prospective Study of t(4;14) Multiple Myeloma Blood, 2007, 110, 414-414.	0.6	0
143	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006, 107, 3053-3057.	0.6	390
144	Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. Transplantation, 2006, 82, 1093-1100.	0.5	48

#	Article	IF	CITATIONS
145	Serum Free Light Chain (SFLC) Elevation Is Associated with High β2-Microglobulin and with a Shorter Time to Treatment in Waldenstrol^m Macroglobulinemia (WM) Blood, 2006, 108, 2419-2419.	0.6	2
146	Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL) Blood, 2006, 108, 2764-2764.	0.6	5
147	Prevention of Post Transplantation Lymphoproliferative Disorders by Adapted Management of EBV Reactivations. A Monocentric Prospective Study on 101 Patients Blood, 2006, 108, 2932-2932.	0.6	0
148	Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status. Transplantation, 2005, 80, 176-184.	0.5	65
149	Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study Blood, 2005, 106, 932-932.	0.6	17
150	Lymphoproliferative disorders after liver transplantation. Journal of Hepatology, 2004, 40, 728-735.	1.8	60
151	Fludarabine in Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 239-242.	0.8	15
152	Identification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders. Recent Results in Cancer Research, 2002, 159, 67-80.	1.8	23
153	Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders. Journal of Clinical Oncology, 2001, 19, 772-778.	0.8	211
154	Expansion Of Cd4+cd7-T Cells, A Memory Subset With Preferential Interleukin-4 Production, After Bone Marrow Transplantation. Transplantation, 1997, 64, 1453-1459.	0.5	22